Loading...
Three doses of human papillomavirus (HPV) vaccine are highly effective at preventing persistent HPV infection and precancerous lesions, but administering three doses poses logistical and, in resource-poor countries, financial challenges.
Canadian investigators compared antibody titers in 520 girls aged 9 to 13 years who were randomized to receive either two doses (at 0 and 6 months) or three doses (at 0, 2, and 6 months) of the quadrivalent HPV vaccine (types 6, 11, 16, and 18) and 310 women aged 16 to 26 who received the three-dose schedule.
At 7 months after the first dose, geometric mean titers (GMTs) against all four vaccine genotypes were higher in girls than in women, regardless of dosage schedule. Among girls, GMTs were noninferior in …